ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a press ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...

The average one-year price target for ALX Oncology Holdings (NasdaqGS:ALXO) has been revised to $4.69 / share. This is an increase of 38.00% from the prior estimate of $3.40 dated February 21, 2026.

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies ...

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...

ALX Oncology Holdings ALXO will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ALX Oncology ...

ALX Oncology reported positive interim results from a phase 2 study of a combo drug featuring evorpacept. Evorpacept showed great potential in treating gastric/gastroesophageal junction cancer. The ...